CMC Consulting vs CDMO Services

bio lab

Table of Contents

Share

bio lab

CMC consultants and CDMOs both work on chemistry, manufacturing, and controls, but they sit on opposite sides of the table. Here is how the roles differ, where they overlap, and when a biotech startup needs each one.

TL;DR
  • A CMC consultant works for you. It sets CMC strategy, plans development, reviews data, writes or reviews regulatory sections, and oversees vendors.
  • A CDMO works on your product. It develops processes and manufactures clinical or commercial material in its own GMP facilities.
  • FDA holds the sponsor accountable. Under FDA's quality agreements guidance, the product owner remains responsible for CGMP compliance even when a contract facility does the work.
  • Most successful startups use both: a consultant to choose and manage the right CDMO, and a CDMO to make the material.

What is the difference between CMC consulting and CDMO services?

CMC consulting is advisory work done on the sponsor's behalf; CDMO services are contracted development and manufacturing done in a vendor's facility. A CMC consultant helps a drug developer decide what to make, how to control it, and how to prove it to regulators. A contract development and manufacturing organization (CDMO) then executes much of that plan: it develops the process, runs engineering and GMP batches, tests material, and ships it to the clinic.

The simplest way to see the difference is to ask who each party answers to. A consultant's job is to protect the sponsor's timeline, budget, and regulatory position. A CDMO's job is to deliver the scope in its contract profitably and in compliance with its own quality system. Those goals usually align, but not always, which is why the distinction matters so much for a startup without an internal CMC team.

What a CMC consultant does

A CMC consultant acts as an extension of the sponsor's leadership team. For an early-stage biotech, that often means serving as a fractional head of CMC until the company hires one. Typical work includes:

  • Building the CMC development plan and phase-appropriate control strategy
  • Defining critical quality attributes and the analytical method roadmap
  • Writing requests for proposal, scoring CDMO bids, and running site audits
  • Planning and overseeing technology transfer between labs and sites
  • Authoring or reviewing the CMC sections of pre-IND packages, INDs, and later BLAs or NDAs
  • Reviewing batch records, deviations, and stability data as an independent second set of eyes

Under 21 CFR 312.23, an IND must include chemistry, manufacturing, and control information, with the emphasis in early phases on identifying and controlling raw materials and the drug substance. A consultant makes sure that information is complete, consistent, and defensible before it reaches FDA. Our guide to pre-IND CMC documentation covers that package in detail.

What a CDMO does

A CDMO provides the people, equipment, and licensed GMP facilities that most startups cannot afford to build. Depending on the provider, services can include cell line or process development, scale-up, drug substance manufacturing, formulation, fill and finish, release and stability testing, and packaging. Many large CDMOs also offer regulatory writing for the work they perform.

The CDMO model gives startups access to capacity and expertise on demand. The demand side shows in the market: BCC Research values the global CDMO market at $136.6 billion in 2024 and projects it to reach $191.6 billion by 2029.

Global CDMO market size, 2023 to 2029Line chart. USD billions: 2023 128.0, 2024 136.6, 2029 191.6 reported by BCC Research; 2025 to 2028 derived from the 7.0% CAGR.$100B$120B$140B$160B$180B$200B$128.0B2023$136.6B20242025202620272028$191.6B2029Year (solid points reported; open points derived from CAGR)
Source: BCC Research, Global CDMO Market (press release, January 2025). The 2023, 2024, and 2029 values are as reported. The 2025 to 2028 values are derived from the reported 7.0% compound annual growth rate and are not separately published figures.

A growing market also means more choice and more variation in quality. Capacity for complex modalities such as AAV, cell therapy, and ADCs remains tight, and startups often compete with larger sponsors for slots. Our framework for buying CDMO capacity covers how to approach that market.

CMC consulting vs. CDMO services: side-by-side comparison

CMC consultantCDMO
Primary roleStrategy, planning, oversight, and regulatory contentProcess development, manufacturing, and testing
Who it representsThe sponsorItself, under contract to the sponsor
Owns facilitiesNoYes, licensed GMP sites
Typical deliverablesCMC plans, RFPs, audits, gap assessments, IND and BLA sections, data reviewBatches, batch records, certificates of analysis, stability data, tech transfer reports
Commercial modelHourly, milestone, or fractional retainerWork orders per batch, campaign, or service
Regulatory accountabilitySupports the sponsor, who remains accountableResponsible for its own CGMP compliance; sponsor remains accountable for the product
Best engagedBefore vendor selection and through each phaseOnce the process, scope, and quality agreement are defined

Why the sponsor stays accountable

Outsourcing manufacturing does not outsource responsibility. FDA's quality agreements guidance states that the product owner remains responsible for ensuring its products are made in compliance with CGMP, even when a quality agreement assigns an activity to the contract facility.

"The owner remains responsible for ensuring its products are made in compliance with CGMP."FDA, Contract Manufacturing Arrangements for Drugs: Quality Agreements, November 2016

That accountability has real consequences. At a Duke-Margolis Institute meeting on CDER biologics applications, FDA presenters reported that contract manufacturing sites accounted for about half of the complete response letters they reviewed. A separate Pharma Manufacturing analysis of 202 complete response letters that FDA published in 2025 found that 74% cited quality or manufacturing issues. A sponsor that relies entirely on its CDMO to catch problems has no independent check before the application goes in.

When a biotech startup needs each one

The balance shifts as a program matures. Early on, strategy matters most; later, execution volume dominates.

StageCMC consultant focusCDMO focus
Preclinical / pre-INDCMC plan, target product profile, CDMO selection, pre-IND packageFeasibility, process development, toxicology material
Phase 1IND CMC section, phase-appropriate specifications, oversightGMP batches, release testing, early stability
Phase 2Process characterization plan, comparability strategy, second-source planningScale-up, process improvements, expanded stability
Phase 3 / BLA or NDAValidation strategy, PAI readiness, Module 3 authoring and reviewProcess performance qualification, commercial-scale batches
CommercialLifecycle management, post-approval changes, supplier oversightRoutine supply, continued process verification

Teams also need people trained to work in this environment. Workforce programs such as NC State's Biomanufacturing Training and Education Center exist because hands-on biomanufacturing skills remain scarce, which is one more reason small companies lean on outside expertise.

How CMC consultants and CDMOs work together

The strongest programs treat the consultant and the CDMO as partners with different jobs. The consultant translates the sponsor's goals into a clear scope and a quality agreement, then monitors execution. The CDMO runs the process and raises issues early. In practice, that looks like:

  • Joint kickoff and governance: shared timelines, decision rights, and escalation paths agreed before the first batch.
  • Person-in-plant support: a sponsor representative on site for critical runs and tech transfer.
  • Independent data review: batch records, deviations, and out-of-specification investigations reviewed by someone who does not work for the CDMO.
  • Stability and specification decisions: owned by the sponsor, supported by tools such as an ICH Q1E shelf-life estimate and phase-appropriate limits.

Warning signs you are relying too heavily on your CDMO

  • No one at your company can explain the control strategy without calling the CDMO.
  • The CDMO wrote the IND CMC section and no independent expert reviewed it.
  • Your quality agreement is the CDMO's template, unchanged.
  • You learn about deviations at the end of a campaign instead of within days.
  • Changing CDMOs would mean starting your process and methods over.

If two or more of these apply, an independent CMC review is usually worth the cost. Our process development, quality control, and quality assurance teams support startups through every stage, and our article on CMC consulting strategies covers common regulatory hurdles.

Choosing a CDMO, or not sure yours is on track?

DES Pharma's senior CMC consultants help biotech startups plan development, select and audit CDMOs, and prepare CMC sections that hold up in FDA review.

Request a meeting

CMC consulting vs. CDMO services: FAQ

Is a CMC consultant the same as a CDMO?

No. A CMC consultant advises the sponsor: it designs the CMC strategy, reviews data, writes or reviews regulatory sections, and oversees vendors. A CDMO is a contract organization that develops processes and manufactures material in its own GMP facilities. Many programs use both, with the consultant acting on the sponsor's side of the relationship.

Can a CDMO handle my CMC regulatory strategy?

Many CDMOs offer regulatory support for the work they perform, and it can be useful. But the CDMO is a vendor with its own commercial interests, and it only sees part of your program. FDA holds the sponsor responsible for CGMP compliance and for the accuracy of the CMC section, so most startups keep strategy and final review on the sponsor side.

When should a biotech startup hire a CMC consultant?

Ideally before selecting a CDMO, usually 12 to 18 months before the planned IND. That leaves time to define the target product profile, plan phase-appropriate analytics, write a strong request for proposal, and avoid locking into a process or vendor that will not scale.

How much does CMC consulting cost compared with CDMO services?

CDMO budgets are typically much larger because they cover facilities, materials, batches, and testing. Consulting is billed by the hour, by milestone, or as a fractional head of CMC, and usually represents a small share of total CMC spend. Its value comes from preventing failed batches, repeat tech transfers, and avoidable regulatory delays.

Does using a CDMO reduce my regulatory risk?

Only if the CDMO is well qualified and well managed. Contract sites still receive inspection findings, and FDA presenters at a Duke-Margolis meeting reported that contract manufacturing sites accounted for about half of the biologics complete response letters they reviewed. Oversight, quality agreements, and person-in-plant support reduce that risk.

About DES Pharma Consulting. DES Pharma Consulting (Dynamic Engineering Solutions) is a New York based pharmaceutical consulting firm that supports drug, biologic, and advanced therapy developers with CMC strategy, process development, analytical development and quality control, quality assurance, supply chain, and pharmacovigilance, from preclinical work through commercial launch. Contact our team to discuss your program.

Share

More Insights:

Connect With Our Team TodayAdvance Your Drug Program
with Confidence

Start building reliable, high-quality drug development programs today.